A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Fowler et al., NCT04330690, CATCO, NCT04330690, May 2024

Artemisinin for COVID-19

46th treatment shown to reduce risk in November 2022, now with p = 0.0066 from 3 studies, recognized in 13 countries.
Lower risk for recovery.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 966 patient artemisinin late treatment RCT with results not reported over 2 years after estimated completion.
2 artemisinin RCTs have results missing long after expected1,2
The trials report an estimated total of 1,366 patients.
Study covers LSALT peptide and artemisinin.
Fowler et al., 18 May 2024, Randomized Controlled Trial, Canada, trial NCT04330690 (history) (CATCO). Contact: rob.fowler@sunnybrook.ca, CATCO@sunnybrook.ca, atrembla@ucalgary.ca, cjdumonc@ucalgary.ca, conar@ualberta.ca, Matt.Munan@covenanthealth.ca, wendy.sligl@ahs.ca, Kimberly.Robertson2@albertahealthservices.ca, Caitlyn.Marek@interiorhealth.ca, Mai.Hayashi@interiorhealth.ca, james.douglas@vch.ca, Valla.sahraei@vch.ca, jennifer.grant@vch.ca, Gabriel.Loh@vch.ca, allimah@mail.ubc.ca, laura.oliveira@ubc.ca, npress@cfenet.ubc.ca, llove@cheos.ubc.ca, daniel.ovakim@viha.ca, fiona.auld@viha.ca, yoav.keynan@umanitoba.ca, nchoi@hsc.mb.ca, Peter.Daley@easternhealth.ca, laura.genge@easternhealth.ca, lisa.barrett@nshealth.ca, barbara.goodall@nshealth.ca, Alexandra.Binnie@williamoslerhs.ca, sergio.borgia@williamoslerhs.ca, thomas.havey@williamoslerhs.ca, Erick.duan@medportal.ca, clarkef@mcmaster.ca, Michael.Silverman@sjhc.london.on.ca, SeemaNair.Parvathy@sjhc.london.on.ca, efera@msh.on.ca, nshah@msh.on.ca, Christopher.Graham@thp.ca, Mobina.Khurram@thp.ca, senglish@ohri.ca, iwatpool@ohri.ca, nicolaschagnon@montfort.on.ca, christinencompas@montfort.on.ca, rporteous@ohri.ca, jennifer.tsang@mail.utoronto.ca, Lisa.patterson@niagarahealth.on.ca, sjohn@shn.ca, crobb@shn.ca, gambleg@me.com, moonl@tbh.net, christopher.kandel@one-mail.on.ca, jeff.powis@tehn.ca, Asgar.Rishu@sunnybrook.ca, Darrell.tan@gmail.com, Attia.Qamar@unityhealth.to, michael.fralick@sinaihealth.ca, bryan.Coburn@uhn.ca, kevin.schwartz@unityhealth.to, kanthi.kavikondala@unityhealth.to, madeleine.durand.chum@ssss.gouv.qc.ca, stephanie.matte.chum@ssss.gouv.qc.ca, matthew.cheng@mcgill.ca, sondramandy.sinanan@muhc.mcgill.ca, alexis.turgeon@crchudequebec.ulaval.ca, David.Bellemare@crchudequebec.ulaval.ca, francois.lellouche@criucpq.ulaval.ca, patricia.lizotte@criucpq.ulaval.ca, francois.lamontagne@usherbrooke.ca, marie-pier.bouchard.ciussse-chus@ssss.gouv.qc.ca.
Late treatment
is less effective